PDIA4

Across TCGA pan-cancer cohorts, PDIA4 Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated PDIA4 data layer compared with 28 for mass-spec protein and 4 for mass-spec protein.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher PDIA4 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated PDIA4 expression acts as an unfavorable survival marker, although some lineages such as UCEC and MESO show a favorable association.

LUAD, BLCA, and COAD are the cancer types where PDIA4 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Median	All	0.503	0.816	<.001	35	view →
BLCA	OS	Median	All	0.069	0.688	<.001	18	view →
COAD	OS	Median	III,IV	0.208	0.791	.008	9	view →
UCEC	DFS	Median	All	0.953	0.629	.033	4	view →
MESO	DFS	Median	All	1.000	0.194	.046	1	view →
SKCM	DFS	Median	III,IV	0.813	0.488	.038	1	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

PDIA4–LUAD (OS)

Open the LUAD breakdown →